hers semaglutide VIEW Hims and Health's compounded Wegovy pill offering fuels market jitters for hers semaglutide Hims &

those technology products

Each peptide addresses distinct aspects of the bodys response to rapid transformation while avoiding mechanistic overlap with the triple agonist itself

is ideal for those looking to enhance workout results, maintain focus, and support their fitness goals with a convenient 30-day supply

Leading GLP-1s expected to reach $50B in 2025 sales Novos Ozempic expected to retain top spot, with similarly large growth rates anticipated for Novos Wegovy and Lillys tirzepatide franchises By the end of 2025, consensus analyst estimates peg the combined sales of the four leading GLP-1 therapies, two apiece from Novo Nordisk and Eli Lilly, at about $50 billion